Eflornithine hydrochloride

DRUG2 trials

Sponsors

Allergan, Children's Oncology Group

Conditions

High Risk NeuroblastomaHirsutismRecurrent NeuroblastomaRefractory Neuroblastoma

Phase 2

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Active, not recruitingNCT03794349

Children's Oncology GroupHigh Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma

Start: 2019-07-08End: 2029-03-31Updated: 2026-02-18

Phase 4

Evaluation of Eflornithine on Facial and Forearm Skin

CompletedNCT00152048

AllerganHirsutism

Start: 2004-11-30End: 2005-10-31Target: 78Updated: 2019-10-30

Related Papers

A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report.

Journal of Clinical Oncology2025-05-282 citations

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.

2024-01-1011 citations

Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone

Molecular Cancer Therapeutics2023-12-011 citations